Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura

Autor: Peyvandi, F., Scully, M., Kremer Hovinga, J.A., Knöbl, P., Cataland, S., De Beuf, K., Callewaert, F., De Winter, H., Zeldin, R.K. *
Zdroj: In Journal of Thrombosis and Haemostasis July 2017 15(7):1448-1452
Databáze: ScienceDirect
Externí odkaz: